GILD Stock: Gilead Sciences, Inc. Stock Price, Analysis & Insights
Get live gild stock price $118.84, comprehensive Gilead Sciences, Inc. stock analysis, charts, news, and expert forecast. Real-time gild stock data and investment insights.
Loading chart...
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Information
- CEO
- Daniel P. O'Day
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17600
Contact Information
- Website
- https://www.gilead.com
- Address
- 333 Lakeside Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 147.5 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 14.5)
✓ Lower volatility stock (Beta: 0.33) may provide portfolio stability
Business Model & Strategy
Gilead Sciences, Inc. operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, Gilead Sciences, Inc. benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Daniel P. O'Day, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Gilead Sciences, Inc. competes in the Drug Manufacturers - General within the broader Healthcare. With 147.5 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Gilead Sciences, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Gilead Sciences, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Gilead Sciences, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Gilead Sciences, Inc.
- ⚠Investors should consider how Gilead Sciences, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
147.46B
P/E Ratio
14.51
Beta
0.33
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 147.46B market capitalization
- Trading Volume: 9.04M shares traded today
- Price Range: 52-week range of $86.08 - $124.61
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 147.46B, the company represents a significant player in its market. The stock is currently trading at $118.84 with a negativedaily change of 3.70%.
The company's 17600 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 14.51, beta of 0.33, and 52-week price range from $86.08 to $124.61when evaluating investment opportunities.
Why Invest in Gilead Sciences, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Daniel P. O'Day
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.